Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more

Recent & Breaking News (NDAQ:BCRX)

BioCryst Reports Fourth Quarter and Full Year 2013 Financial Results

GlobeNewswire February 26, 2014

BioCryst Announces Peramivir NDA Acceptance by the FDA

GlobeNewswire February 25, 2014

BioCryst to Present at Three Upcoming Investor Conferences

GlobeNewswire February 20, 2014

BioCryst to Announce Fourth Quarter and 2013 Financial Results February 26

GlobeNewswire February 12, 2014

RDInvesting Provides Investors with Free In-Depth Equity Reports on BCRX, ENTA, IDIX and RPTP

Accesswire January 29, 2014

BioCryst to Present at J.P. Morgan Healthcare Conference

Globe Newswire January 2, 2014

BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Marburg Virus Disease

Business Wire December 30, 2013

BioCryst Files Peramivir NDA for the Treatment of Influenza

Business Wire December 20, 2013

Notable Buzzers: Questcor Pharmaceuticals, Omeros Corporation, BioCryst Pharmaceuticals, Baidu Inc

Accesswire December 18, 2013

BioCryst Advances Second Generation Oral Plasma Kallikrein Inhibitors for Hereditary Angioedema into Preclinical Development

Business Wire December 18, 2013

Annual Changes to the NASDAQ Biotechnology Index

Globe Newswire December 16, 2013

BioCryst to Present at Two Upcoming Investor Conferences

Business Wire November 20, 2013

BioCryst Initiates OPuS-1: a Phase 2a Clinical Trial of BCX4161 in Patients with Hereditary Angioedema

Business Wire November 7, 2013

BioCryst Provides Corporate Update and Reports Third Quarter 2013 Financial Results

Business Wire November 5, 2013

BioCryst to Announce Third Quarter 2013 Financial Results November 5

Business Wire October 23, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on BCRX, INCY, LXRX and SNSS

Accesswire September 27, 2013

BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases (NIAID) to Develop BCX4430 for the Treatment of Marburg Virus Disease

Business Wire September 17, 2013

BioCryst to Present at Morgan Stanley Global Healthcare Conference

Business Wire September 3, 2013

InvestorsGuru.com 39 Filtered Mid-Day Market Movers Recap

Investors Guru September 1, 2013

BioCryst Provides Corporate Update and Reports Second Quarter 2013 Financial Results

Business Wire August 8, 2013